Skip to main content

Articles

Page 1 of 63

  1. Diabetes mellitus (DM) is a metabolic disease that heightens the risks of many vascular complications, including peripheral arterial disease (PAD). Various types of cells, including but not limited to endothel...

    Authors: Alonso Tapia, Xuejing Liu, Naseeb Kaur Malhi, Dongqiang Yuan, Muxi Chen, Kevin W. Southerland, Yingjun Luo and Zhen Bouman Chen
    Citation: Cardiovascular Diabetology 2024 23:274
  2. Extracellular matrix (ECM) stiffness is closely related to the progress of diabetic cardiomyopathy (DCM) and the response of treatment of DCM to anti-diabetic drugs. Dapagliflozin (Dapa) has been proven to hav...

    Authors: Tong Zhu, Zhaoyang Ye, Jingjing Song, Junjie Zhang, Yuxiang Zhao, Feng Xu, Jun Wang, Xin Huang, Bin Gao and Fei Li
    Citation: Cardiovascular Diabetology 2024 23:273
  3. Metabolic syndrome (MetS) is a cluster of medical conditions and risk factors correlating with insulin resistance that increase the risk of developing cardiometabolic health problems. The specific criteria for...

    Authors: Rubén Gil-Redondo, Ricardo Conde, Chiara Bruzzone, Maria Luisa Seco, Maider Bizkarguenaga, Beatriz González-Valle, Angela de Diego, Ana Laín, Hansjörg Habisch, Christoph Haudum, Nicolas Verheyen, Barbara Obermayer-Pietsch, Sara Margarita, Serena Pelusi, Ignacio Verde, Nádia Oliveira…
    Citation: Cardiovascular Diabetology 2024 23:272
  4. Authors: Vera H. W. de Wit‑Verheggen, Sibel Altintas, Romy J. M. Spee, Casper Mihl, Sander M. J. van Kuijk, Joachim E. Wildberger, Vera B. Schrauwen‑Hinderling, Bas L. J. H. Kietselaer and Tineke van de Weijer
    Citation: Cardiovascular Diabetology 2024 23:271

    The original article was published in Cardiovascular Diabetology 2020 19:129

  5. A significant percentage of patients with acute coronary syndrome (ACS) without standard modifiable cardiovascular risk factors (SMuRFs) are being identified. Nonetheless, the prognostic influence of the TyG i...

    Authors: Xiaoming Zhang, Yu Du, Tianhao Zhang, Zehao Zhao, Qianyun Guo, Xiaoteng Ma, Dongmei Shi and Yujie Zhou
    Citation: Cardiovascular Diabetology 2024 23:270
  6. Heart failure with preserved ejection fraction (HFpEF) is a mortal clinical syndrome without effective therapies. Empagliflozin (EMPA) improves cardiovascular outcomes in HFpEF patients, but the underlying mec...

    Authors: Ying Shi, Lili Zhao, Jing Wang, Xiankun Liu, Yiming Bai, Hongliang Cong and Ximing Li
    Citation: Cardiovascular Diabetology 2024 23:269
  7. Ischemia with non-obstructive coronary artery (INOCA) is a common cause of hospital admissions, leading to negative outcomes and reduced quality of life. Central to its pathophysiology is endothelial dysfuncti...

    Authors: Marco Ferrone, Michele Ciccarelli, Fahimeh Varzideh, Urna Kansakar, Germano Guerra, Federica Andrea Cerasuolo, Antonietta Buonaiuto, Antonella Fiordelisi, Enzo Venga, Mafalda Esposito, Antonio Rainone, Roberto Ricciardi, Carmine Del Giudice, Fabio Minicucci, Tullio Tesorio, Valeria Visco…
    Citation: Cardiovascular Diabetology 2024 23:268
  8. Sodium–Glucose Cotransporter-2 Inhibitor (SGLT2i) is a novel oral drug for treating type 2 diabetes mellitus (T2DM) with demonstrated cardiovascular benefits. Previous studies in apolipoprotein E knockout mice...

    Authors: Tianhao Zhang, Xuelian Gao, Tianlong Chen, Hongkai Zhang, Xiaoming Zhang, Yu Xin, Dongmei Shi, Yu Du, Lei Xu and Yujie Zhou
    Citation: Cardiovascular Diabetology 2024 23:267
  9. Heart failure with reduced ejection fraction (HFrEF) is associated with a high rate of mortality and morbidity. Evidence has shown that sex differences may be an important contributor to phenotypic heterogenei...

    Authors: Ke Shi, Ge Zhang, Hang Fu, Xue-Ming Li, Li Jiang, Yue Gao, Wen-Lei Qian, Li-Ting Shen, Hua-Yan Xu, Yuan Li, Ying-Kun Guo and Zhi-Gang Yang
    Citation: Cardiovascular Diabetology 2024 23:266
  10. The role of lifestyle factors and their relative contributions to the development and mortality of cardio-renal-metabolic multimorbidity (CRMM) remains unclear.

    Authors: Ning Zhang, Xiang Liu, Lele Wang, Yuan Zhang, Yi Xiang, Jiajie Cai, Hao Xu, Xiong Xiao and Xing Zhao
    Citation: Cardiovascular Diabetology 2024 23:265
  11. Atherogenic index of plasma (AIP) has been reported as a critical predictor on the risks and clinical outcomes of cardiovascular diseases (CVDs), and we aimed to explore the potential predictive value of cumul...

    Authors: Zhihao Liu, Long Zhang, Leyi Wang, Kaiyin Li, Fangfang Fan, Jia Jia, Jianping Li and Yan Zhang
    Citation: Cardiovascular Diabetology 2024 23:264
  12. The beneficial effects of fenofibrate on atherosclerotic cardiovascular disease (ASCVD) outcomes in patients with diabetes and statin treatment are unclear. We investigated the effects of fenofibrate on all-ca...

    Authors: Sangmo Hong, Kyung-Soo Kim, Kyungdo Han and Cheol-Young Park
    Citation: Cardiovascular Diabetology 2024 23:263
  13. The relationship between the triglyceride-glucose (TyG) index and its derived index, the triglyceride glucose-waist height ratio (TyG-WHtR), with mortality and cardiovascular diseases (CVDs) in patients with n...

    Authors: Yusha Zhang, Fengjiao Wang, Jianjun Tang, Li Shen, Jia He and Yaqin Chen
    Citation: Cardiovascular Diabetology 2024 23:262
  14. Mitochondria play a central role in cellular energy metabolism, and their dysfunction is increasingly recognized as a critical factor in the pathogenesis of diabetes-related cardiac pathophysiology, including vu...

    Authors: Michael W. Rudokas, Margaret McKay, Zeren Toksoy, Julia N. Eisen, Markus Bögner, Lawrence H. Young and Fadi G. Akar
    Citation: Cardiovascular Diabetology 2024 23:261
  15. Type I and type II diabetes mellitus (DM) patients have a higher prevalence of cardiovascular diseases, as well as a higher mortality risk of cardiovascular diseases and interventions. This study provides an u...

    Authors: S. R. Slingerland, D. N. Schulz, G. J. van Steenbergen, M. A. Soliman-Hamad, J. M. H. Kisters, M. Timmermans, K. Teeuwen, L. Dekker and D. van Veghel
    Citation: Cardiovascular Diabetology 2024 23:260
  16. The main goal of this study was to examine how diabetes, cardiovascular calcification characteristics and other risk factors affect mortality in end-stage renal disease (ESRD) patients in the early stages of h...

    Authors: Qingxian Li, Peishan Li, Zigan Xu, ZeYuan Lu, Chuan Yang and Jie Ning
    Citation: Cardiovascular Diabetology 2024 23:259
  17. Insulin signaling regulates cardiac substrate utilization and is implicated in physiological adaptations of the heart. Alterations in the signaling response within the heart are believed to contribute to patho...

    Authors: Jonathan Samuel Achter, Estefania Torres Vega, Andrea Sorrentino, Konstantin Kahnert, Katrine Douglas Galsgaard, Pablo Hernandez-Varas, Michael Wierer, Jens Juul Holst, Jørgen Frank Pind Wojtaszewski, Robert William Mills, Rasmus Kjøbsted and Alicia Lundby
    Citation: Cardiovascular Diabetology 2024 23:258
  18. Diabetes mellitus (DM) and Lp(a) are well-established predictors of coronary artery disease (CAD) outcomes. However, their combined association remains poorly understood.

    Authors: Arthur Shiyovich, Adam N. Berman, Stephanie A. Besser, David W. Biery, Rhanderson Cardoso, Sanjay Divakaran, Avinainder Singh, Daniel M. Huck, Brittany Weber, Jorge Plutzky, Christopher Cannon, Khurram Nasir, Marcelo F. Di Carli, James L. Januzzi, Deepak L. Bhatt and Ron Blankstein
    Citation: Cardiovascular Diabetology 2024 23:257
  19. BMI variability has been associated with increased cardiovascular disease risk in individuals with type 2 diabetes, however comparison between clinical studies and real-world observational evidence has been la...

    Authors: Robert J. Massey, Yu Chen, Marina Panova-Noeva, Michaela Mattheus, Moneeza K. Siddiqui, Nanette C. Schloot, Antonio Ceriello, Ewan R. Pearson and Adem Y. Dawed
    Citation: Cardiovascular Diabetology 2024 23:256
  20. The atherogenic index of plasma (AIP) is a critical metric for predicting cardiovascular outcomes. However, its associations with cardiovascular disease mortality (CVM) and all-cause mortality (ACM) remain unc...

    Authors: Minghui Qin and Bo Chen
    Citation: Cardiovascular Diabetology 2024 23:255
  21. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic condition that is characterized by unresolved fatigue, post-exertion symptom exacerbation (PESE), cognitive dysfunction, or...

    Authors: Massimo Nunes, Mare Vlok, Amy Proal, Douglas B. Kell and Etheresia Pretorius
    Citation: Cardiovascular Diabetology 2024 23:254
  22. Type 2 diabetes (T2D) patients have an increased risk of heart failure (HF). There are limited data on the association between HF and T2D in specific healthcare settings. This study sought to analyse the preva...

    Authors: Rafael Gonzalez-Manzanares, María Anguita-Gámez, Javier Muñiz, Vivencio Barrios, José Antonio Gimeno-Orna, Antonio Pérez, Luis Rodríguez-Padial and Manuel Anguita
    Citation: Cardiovascular Diabetology 2024 23:253
  23. Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) were initially recommended as oral anti-diabetic drugs to treat type 2 diabetes (T2D), by inhibiting SGLT2 in proximal tubule and reduce renal reabsorpti...

    Authors: Hong-Yi Duan, Hector Barajas-Martinez, Charles Antzelevitch and Dan Hu
    Citation: Cardiovascular Diabetology 2024 23:252
  24. The triglyceride-glucose (TyG) index is associated with the development and prognosis of coronary artery disease (CAD). However, the impact of the TyG index on CAD severity across different glucose metabolism ...

    Authors: Sheng Zhao, Zuoxiang Wang, Ping Qing, Minghui Li, Qingrong Liu, Xuejie Pang, Keke Wang, Xiaojin Gao, Jie Zhao and Yongjian Wu
    Citation: Cardiovascular Diabetology 2024 23:251
  25. Individuals with type 2 diabetes (T2D) face an increased mortality risk, not fully captured by canonical risk factors. Biological age estimation through DNA methylation (DNAm), i.e. the epigenetic clocks, is emer...

    Authors: Jacopo Sabbatinelli, Angelica Giuliani, Katarzyna Malgorzata Kwiatkowska, Giulia Matacchione, Alessia Belloni, Deborah Ramini, Francesco Prattichizzo, Valeria Pellegrini, Francesco Piacenza, Elena Tortato, Anna Rita Bonfigli, Davide Gentilini, Antonio Domenico Procopio, Paolo Garagnani, Fabiola Olivieri and Giuseppe Bronte
    Citation: Cardiovascular Diabetology 2024 23:250
  26. Previous studies have shown that peptides encoded by noncoding RNAs (ncRNAs) can be used as peptide drugs to alleviate diseases. We found that microRNA-31 (miR-31) is involved in the regulation of hypertension...

    Authors: Xiangxiao Li, Hong Zhou, Pengfei Lu, Zilong Fang, Guangzheng Shi, Xinran Tong, Wendong Chen, Gonghao Jiang, Peili Zhang, Jingyan Tian and Qun Li
    Citation: Cardiovascular Diabetology 2024 23:249
  27. The effect of empagliflozin, a sodium-glucose-co-transporter-2 inhibitor, on risk for myocardial infarction has not been fully characterized.

    Authors: David Fitchett, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Stefan D. Anker, Stuart Pocock, Michaela Mattheus, Ola Vedin and Søren S. Lund
    Citation: Cardiovascular Diabetology 2024 23:248
  28. The triglyceride-glucose (TyG) index and its combination with obesity indicators can predict cardiovascular diseases (CVD). However, there is limited research on the relationship between changes in the triglyc...

    Authors: Qiushi Ren, Yang Huang, Quan Liu, Tongxin Chu, Gang Li and Zhongkai Wu
    Citation: Cardiovascular Diabetology 2024 23:247
  29. This study quantifies the longitudinal economic burden for a wide spectrum of incident complications, metabolic syndrome (MS)-related risk factors, and comorbidities in patients with MS.

    Authors: Kah Suan Chong, Yi-Hsin Chang, Chun-Ting Yang, Chu-Kuang Chou, Huang‑Tz Ou and Shihchen Kuo
    Citation: Cardiovascular Diabetology 2024 23:246
  30. Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD) has been associated with increased cardiovascular risk. The aim of this Randomized Double-blind clinical Trial was to evaluate the effects of co...

    Authors: Emmanouil Vrentzos, Ignatios Ikonomidis, George Pavlidis, Konstantinos Katogiannis, Emmanouil Korakas, Aikaterini Kountouri, Loukia Pliouta, Eleni Michalopoulou, Emilia Pelekanou, Dimitrios Boumpas and Vaia Lambadiari
    Citation: Cardiovascular Diabetology 2024 23:245
  31. To adapt risk prediction equations for myocardial infarction (MI), stroke, and heart failure (HF) among patients with type 2 diabetes in real-world settings using cross-institutional electronic health records ...

    Authors: Chun-Ting Yang, Kah Suan Chong, Chi-Chuan Wang, Huang-Tz Ou and Shihchen Kuo
    Citation: Cardiovascular Diabetology 2024 23:244
  32. The prevalence of obesity-associated insulin resistance (IR) is increasing along with the increase in obesity rates. In this study, we compared the predictive utility of four alternative indexes of IR [triglyc...

    Authors: Mingxuan Duan, Xi Zhao, Shaolin Li, Guangrui Miao, Linpeng Bai, Qingyang Zhang, Wenxuan Yang and Xiaoyan Zhao
    Citation: Cardiovascular Diabetology 2024 23:243
  33. Tirzepatide is a new drug targeting glucagon-like peptide 1(GLP1) and gastric inhibitory polypeptide (GIP) receptors. This drug has demonstrated great potential in improving the clinical outcomes of patients w...

    Authors: Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, Ada Pesapane, Manuela Giovanna Basilicata, Puja Ghosh, Martina Franzese, Giovanni Tortorella, Armando Puocci, Maria Teresa Vietri, Annalisa Capuano, Giuseppe Paolisso and Michelangela Barbieri
    Citation: Cardiovascular Diabetology 2024 23:242
  34. Cardiovascular disease remains the primary cause of morbidity and mortality despite advancements in the treatment of patients with type 2 diabetes. Effective diabetes management extends beyond blood glucose co...

    Authors: Katrine Schultz Overgaard, Roda Abdulkadir Mohamed, Thomas Rueskov Andersen, Jess Lambrechtsen, Kenneth Egstrup and Søren Auscher
    Citation: Cardiovascular Diabetology 2024 23:241
  35. Metabolism is increasingly recognized as a key regulator of the function and phenotype of the primary cellular constituents of the atherosclerotic vascular wall, including endothelial cells, smooth muscle cell...

    Authors: Han Jin, Cheng Zhang, Jan Nagenborg, Peter Juhasz, Adele V. Ruder, Cornelis J. J. M. Sikkink, Barend M. E. Mees, Olivia Waring, Judith C. Sluimer, Dietbert Neumann, Pieter Goossens, Marjo M. P. C. Donners, Adil Mardinoglu and Erik A. L. Biessen
    Citation: Cardiovascular Diabetology 2024 23:240
  36. Type 2 diabetes (T2D) is a frequent comorbidity encountered in patients with severe aortic stenosis (AS), leading to an adverse left ventricular (LV) remodeling and dysfunction. Metabolic alterations have been...

    Authors: Maelle Cherpaz, Emmanuelle Meugnier, Gaultier Seillier, Matteo Pozzi, Romain Pierrard, Simon Leboube, Fadi Farhat, Marco Vola, Jean-François Obadia, Camille Amaz, Lara Chalabreysse, Chloe May, Stephanie Chanon, Camille Brun, Lucas Givre, Gabriel Bidaux…
    Citation: Cardiovascular Diabetology 2024 23:239
  37. Atherogenic index of plasma (AIP) is a non-traditional lipid parameter that can reflect the burden of atherosclerosis. A lipid profile resembling atherosclerosis emerged during pregnancy. Although lipid metabo...

    Authors: Juan Zhang, Yaoyu Suo, Li Wang, Dong Liu, Yue Jia, Yajuan Fu, Weining Fan and Yideng Jiang
    Citation: Cardiovascular Diabetology 2024 23:237
  38. Owing to its unique location and multifaceted metabolic functions, epicardial adipose tissue (EAT) is gradually emerging as a new metabolic target for coronary artery disease risk stratification. Microvascular...

    Authors: Jinxuan Zhao, Wei Cheng, Yang Dai, Yao Li, Yuting Feng, Ying Tan, Qiucang Xue, Xue Bao, Xuan Sun, Lina Kang, Dan Mu and Biao Xu
    Citation: Cardiovascular Diabetology 2024 23:236
  39. Despite improved glycemic treatment, the impact of glycation on pathological consequences may persist and contribute to adverse clinical outcomes in diabetes. In the present study we ...

    Authors: Krishna Adeshara, Daniel Gordin, Anni A. Antikainen, Valma Harjutsalo, Niina Sandholm, Markku J. Lehto and Per-Henrik Groop
    Citation: Cardiovascular Diabetology 2024 23:235
  40. The abnormal low-density protein cholesterol (LDL-C) level in the development of atherosclerosis is often comorbid in individuals with type 2 diabetes mellitus(T2DM). This study aimed to investigate the aggrav...

    Authors: Yi-Ning Jiang, Yue Gao, Yu-Shan Zhang, Chen-Yan Min, Li-Ting Shen, Wei-Feng Yan, Zhi-Gang Yang, Rui Shi and Yuan Li
    Citation: Cardiovascular Diabetology 2024 23:234
  41. Artificial sweeteners are widely popular worldwide as substitutes for sugar or caloric sweeteners, but there are still several important unknowns and controversies regarding their associations with cardiovascu...

    Authors: Tao Sun, Juan Yang, Fang Lei, Xuewei Huang, Weifang Liu, Xingyuan Zhang, Lijin Lin, Linsu Sun, Xinlan Xie, Xiao-Jing Zhang, Jingjing Cai, Zhi-Gang She, Chengsheng Xu and Hongliang Li
    Citation: Cardiovascular Diabetology 2024 23:233
  42. The prognostic value of triglyceride-glucose (TyG) related indices in non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD) is still unclear. This study ...

    Authors: Qingling Chen, Pingping Hu, Xiaoxue Hou, Ye Sun, Mengfan Jiao, linya Peng, Zixing Dai, Xizhi Yin, Rui Liu, Yuwen Li and Chuanlong Zhu
    Citation: Cardiovascular Diabetology 2024 23:232
  43. Associations between metabolic status and metabolic changes with the risk of cardiovascular outcomes have been reported. However, the role of genetic susceptibility underlying these associations remains unexpl...

    Authors: Cancan Li, Xiaoni Meng, Jie Zhang, Haotian Wang, Huimin Lu, Meiling Cao, Shengzhi Sun and Youxin Wang
    Citation: Cardiovascular Diabetology 2024 23:231
  44. The available evidence on the impact of specific non-pharmacological interventions on glycaemic control is currently limited. Consequently, there is a need to determine which interventions could provide the mo...

    Authors: Jacinto Muñoz-Pardeza, José Francisco López-Gil, Nidia Huerta-Uribe, Ignacio Hormazábal-Aguayo, Mikel Izquierdo and Antonio García-Hermoso
    Citation: Cardiovascular Diabetology 2024 23:230
  45. Glucokinase (GK) plays a key role in glucose metabolism. In the liver, GK is regulated by GK regulatory protein (GKRP) with nuclear sequestration at low plasma glucose level. Some GK activators (GKAs) disrupt ...

    Authors: Ke Wang, Mai Shi, Andrea O. Y. Luk, Alice P. S. Kong, Ronald C. W. Ma, Changhong Li, Li Chen, Elaine Chow and Juliana C. N. Chan
    Citation: Cardiovascular Diabetology 2024 23:228
  46. In recent years, the incidence of diabetes has been increasing rapidly, posing a serious threat to human health. Diabetic cardiomyopathy (DCM) is characterized by cardiomyocyte hypertrophy, myocardial fibrosis...

    Authors: Xi Yao, Xinyue Huang, Jianghua Chen, Weiqiang Lin and Jingyan Tian
    Citation: Cardiovascular Diabetology 2024 23:227
  47. The atherogenic index of plasma (AIP) is closely associated with the onset of diabetes, with obesity being a significant risk factor for type 2 diabetes mellitus (T2DM). However, the association between the AI...

    Authors: Yongbing Sun, Fengli Li, Yang Zhou, Ao Liu, Xinbei Lin, Zhi Zou, Xue Lv, Jing Zhou, Zhonglin Li, Xiaoling Wu, Shewei Dou, Michael Zhang, Jiadong Zhu, Yalong Chen, Xinguang Xiao, Yangxi Hu…
    Citation: Cardiovascular Diabetology 2024 23:226
  48. The Triglyceride-glucose (TyG) index, a surrogate marker of insulin resistance, has been implicated in the risk of ischemic stroke. However, the interplay between TyG levels, lifestyle factors, and their colle...

    Authors: Hui Zhou, Xiong Ding, Yulong Lan, Wei Fang, Xiaojie Yuan, Yan Tian, Shuohua Chen, Shouling Wu and Dan Wu
    Citation: Cardiovascular Diabetology 2024 23:225

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 8.5
    5-year Journal Impact Factor: 8.9
    Source Normalized Impact per Paper (SNIP): 1.855
    SCImago Journal Rank (SJR): 2.621

    Speed 2023
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 56

    Usage 2023
    Downloads: 2,523,778
    Altmetric mentions: 3,115